Oncology
Relapsed or Refractory B-Cell Malignancies
0
Pipeline Programs↗
8
Active Trials↗
8
Companies Involved↗
Relapsed or Refractory B-cell Malignancies is an early-stage landscape with 0 programs across 8 companies. The most active players are CRISPR Therapeutics, Newave Pharmaceutical Inc, Ascenta Therapeutics.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
13
clinical trials
Recruiting7 · 54%
Terminated3 · 23%
Completed2 · 15%
Not yet recruiting1 · 8%
Clinical Trials
Trial Activity
13 trials
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Recruiting·—·Phase 1·NCT06980116·50 enrolled
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Not yet recruiting·—·N/A·NCT07476378·69 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)